Clinical trials: Cushing Syndrome

Cushing's Syndrome

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

• Terminated
• Age: 18 to 85 years
• Phase 2
• Results posted

This study will evaluate whether the drug mifepristone can improve the symptoms of Cushing's syndrome in people with ectopic adrenal corticotrophin hormone (ACTH) secretion.

Trial name

NCT00422201

Testing

Mifepristone

Where

15 sites in United States, France and 3 more

Volunteers

18 people

Sponsor

HRA Pharma